IRIS
CAVAZZONI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.148
AS - Asia 7.281
EU - Europa 5.709
SA - Sud America 997
AF - Africa 383
Continente sconosciuto - Info sul continente non disponibili 284
OC - Oceania 10
Totale 23.812
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.956
SG - Singapore 2.558
CN - Cina 1.996
IT - Italia 1.368
VN - Vietnam 1.171
FI - Finlandia 822
IE - Irlanda 789
BR - Brasile 776
SE - Svezia 705
DE - Germania 549
HK - Hong Kong 526
UA - Ucraina 344
FR - Francia 280
ZA - Sudafrica 233
BD - Bangladesh 226
NL - Olanda 226
TR - Turchia 171
IN - India 160
GB - Regno Unito 155
RU - Federazione Russa 126
CA - Canada 110
AT - Austria 84
BE - Belgio 80
AR - Argentina 78
CI - Costa d'Avorio 68
JP - Giappone 47
PL - Polonia 47
IQ - Iraq 46
PK - Pakistan 45
MX - Messico 43
EC - Ecuador 42
KR - Corea 42
ID - Indonesia 39
ES - Italia 36
CO - Colombia 35
PH - Filippine 35
TH - Thailandia 27
CZ - Repubblica Ceca 22
JO - Giordania 22
LT - Lituania 20
MA - Marocco 20
VE - Venezuela 20
UZ - Uzbekistan 18
EG - Egitto 16
AE - Emirati Arabi Uniti 15
JM - Giamaica 15
SA - Arabia Saudita 15
IR - Iran 14
KE - Kenya 14
CL - Cile 13
AZ - Azerbaigian 12
PS - Palestinian Territory 11
BO - Bolivia 9
LB - Libano 9
MY - Malesia 9
IL - Israele 8
PE - Perù 8
PY - Paraguay 8
TN - Tunisia 8
AL - Albania 7
OM - Oman 7
SY - Repubblica araba siriana 7
TW - Taiwan 7
UY - Uruguay 7
AU - Australia 6
KG - Kirghizistan 6
KZ - Kazakistan 6
LU - Lussemburgo 6
NP - Nepal 6
RO - Romania 6
CR - Costa Rica 5
DZ - Algeria 5
MD - Moldavia 5
DO - Repubblica Dominicana 4
ET - Etiopia 4
HN - Honduras 4
HU - Ungheria 4
NZ - Nuova Zelanda 4
CH - Svizzera 3
EU - Europa 3
HR - Croazia 3
PA - Panama 3
QA - Qatar 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
BG - Bulgaria 2
BH - Bahrain 2
CY - Cipro 2
EE - Estonia 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
KW - Kuwait 2
LK - Sri Lanka 2
LV - Lettonia 2
MK - Macedonia 2
PT - Portogallo 2
SC - Seychelles 2
Totale 23.506
Salva come PNG Salva come JPEG
Città #
Singapore 1.320
Ashburn 952
San Jose 882
Dallas 833
Dublin 788
Chandler 744
Santa Clara 512
Ann Arbor 509
Hong Kong 485
Beijing 463
Parma 404
Jacksonville 384
Ho Chi Minh City 345
Council Bluffs 317
Dearborn 281
Hanoi 257
Boardman 256
Johannesburg 223
New York 223
Los Angeles 201
Nanjing 179
Shanghai 170
Munich 164
Lauterbourg 150
Princeton 135
Izmir 133
San Mateo 113
Hefei 111
Milan 111
Helsinki 89
Bremen 86
Wilmington 84
São Paulo 81
Nanchang 72
Buffalo 71
Chicago 69
Vienna 69
Abidjan 68
Brussels 63
Moscow 60
Da Nang 59
Shenyang 58
Kunming 56
Haiphong 53
Marseille 53
Des Moines 52
Bologna 51
The Dalles 51
Toronto 51
Hebei 49
Jinan 49
Modena 48
Frankfurt am Main 47
Tianjin 43
Columbus 41
Houston 41
Rome 40
Guangzhou 39
Woodbridge 39
Turku 37
Tokyo 36
Amsterdam 35
Seattle 35
Warsaw 33
Changsha 31
Jiaxing 29
London 27
Pune 27
Stockholm 27
Rio de Janeiro 25
Denver 24
Levanto 24
Brooklyn 23
Reggio Emilia 23
Jakarta 22
Montreal 22
Redmond 22
Atlanta 21
Quito 21
Phoenix 20
Seoul 20
Wayne 20
Amman 19
Manchester 19
Norwalk 19
Nuremberg 19
Orem 19
Chennai 18
Dhaka 18
San Francisco 18
New Delhi 17
Poplar 17
Tashkent 17
Augusta 16
Zhengzhou 16
Belo Horizonte 15
Boston 15
Brasília 15
Florence 15
Fremont 15
Totale 14.288
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 353
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 285
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 254
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 254
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 249
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model 249
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 222
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 216
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 215
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 212
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 211
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 209
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 209
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 208
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 206
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 206
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 200
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 200
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 197
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 196
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 196
Characterization of gefitinib uptake in NSCLC cell lines 194
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 192
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 191
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 188
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 187
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 186
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 185
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 185
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 184
5-benzylidene-hydantoins as new inhibitors of cell proliferation 183
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma 183
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 180
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 180
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 180
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 180
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 179
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 176
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 176
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 175
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 175
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 174
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 174
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 174
Intrapleural polymeric devices containing Cisplatin for malignant pleural Mesothelioma in a rat tumor model: a preliminary study. 171
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 168
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 168
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 167
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 166
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 165
Cell culture studies of polysaccharide films loaded with cisplatin for the loco-regional therapy of malignant pleural mesothelioma 165
Intrapleural adjuvant treatment of mesothelioma : The combination of cisplatin-pemetrexed in rat tumor model 165
Biological hallmarks and new therapeutic approaches for the treatment of pdac 163
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 161
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 161
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 161
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 160
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 160
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 160
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 160
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 159
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 157
Mannich base derivatives as novel EGFR irreversible inhibitors 153
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 153
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 152
Synergistic activity of letrozole and sorafenib on breast cancer cells 150
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 149
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 149
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 148
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 146
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 146
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 145
Roles of compatible osmolytes and heat shock protein 70 in the induction of tolerance to stresses in porcine endothelial cells 144
Anti-proliferative effect of induced Fhit expression in non small cell lung cancer cell line (Calu-1) 144
New treatment opportunities in phosphatase and tensin homolo(PTen)-deficient tumors: Focus on PTen/focal adhesion kinase pathway 141
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 141
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 141
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 140
PD-L1 OVEREXPRESSION INDUCES ANGIOGENIC CYTOKINE SECRETION AND ENDOTHELIAL CELL MIGRATION VIA STAT SIGNALLING. 139
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 137
Antibacterial and antitumor activity of tetracyclic fluoroquinolones with pyrido[2,3-a]carbazole structure 137
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 137
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 136
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 136
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 136
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 136
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors 136
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 136
State of the art and perspectives in pediatric hepatocellular carcinoma 135
Irreversible EGFR inhibitor compounds with antiproliferative activity 134
Hypertonic stress and amino acid deprivation both increase expression of mRNA for amino acid transport system A 132
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 132
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 132
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 131
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 131
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 130
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 128
New imidazo[2,1-b][1,3,4]thiadiazole aerivatives anhibit FAK phosphorylation and potentiate the antiproliferative effects of gemcitabine through modulation of the human equilibrative nucleoside transporter-1 in peritoneal mesothelioma 127
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 126
null 126
Totale 17.137
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.299
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.299
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022678 0 30 34 48 13 13 100 67 44 59 38 232
2022/20233.019 284 313 209 200 275 341 27 251 955 17 114 33
2023/20241.275 66 96 48 56 104 298 94 82 44 67 125 195
2024/20254.226 133 210 271 313 409 462 247 176 542 355 389 719
2025/20269.282 782 871 1.175 823 1.249 484 1.001 271 1.290 685 394 257
2026/2027686 341 345 0 0 0 0 0 0 0 0 0 0
Totale 23.812